Upcoming trials of TIL therapy in breast cancer include a phase II trial (NCT04111510) is investigating LN-145 TIL therapy in mTNBC, a phase I/II (NCT05451784) trial of PD-L1+ TILs in TNBC, a phase Ib (NCT05576077) study of TBio4101 with pembrolizumab in solid tumors including breast cancer, and a phase II (NCT03449108) trial of LN-145-S1 with ICI in metastatic TNBC. This evidence concerns the gene CD274 and breast carcinoma.